AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
This launch is part of the company's strategy to expand its nutraceutical portfolio
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Subscribe To Our Newsletter & Stay Updated